BHCM
EWTX icon

Brevan Howard Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Brevan Howard Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,561
Closed -$178K – 2027
2025
Q2 		$178K Buy
+13,561
New +$196K ﹤0.01% 1731
2025
Q1 		– Sell
-25,346
Closed -$677K – 1252
2024
Q4 		$677K Buy
25,346
+14,095
+125% +$449K ﹤0.01% 532
2024
Q3 		$300K Buy
+11,251
New +$224K ﹤0.01% 860

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Brevan Howard Capital Management's EWTX Position: Q3 2025 in Review

Brevan Howard Capital Management sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 13,561 shares — an estimated $178K sold.

Brevan Howard Capital Management first reported a position in EWTX in Q3 2024 and held it in 3 quarters. The position peaked at $677K in Q4 2024. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Brevan Howard Capital Management reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,561 Edgewise Therapeutics shares in Q3 2025, an estimated $178K.
  • Brevan Howard Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 3 quarters.
  • Brevan Howard Capital Management's Edgewise Therapeutics position peaked at $677K in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Brevan Howard Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.